keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma with portal vein thrombosis

keyword
https://www.readbyqxmd.com/read/29234631/sorafenib-versus-hepatic-arterial-infusion-chemotherapy-as-initial-treatment-for-hepatocellular-carcinoma-with-advanced-portal-vein-tumor-thrombosis
#1
Michihisa Moriguchi, Takeshi Aramaki, Hideyuki Nishiofuku, Rui Sato, Koiku Asakura, Kanji Yamaguchi, Toshihiro Tanaka, Masahiro Endo, Yoshito Itoh
Objective: To investigate the validity of hepatic arterial infusion chemotherapy with low-dose 5-fluorouracil and cisplatin (LFP) versus sorafenib as first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (Vp3, Vp4). Patients and Methods: We retrospectively reviewed the cases of Child-Pugh A advanced HCC with Vp3 or Vp4 treated with LFP or sorafenib between October 2002 and December 2013. Results: There were 32 patients in the LFP group and 14 patients in the sorafenib group...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29233562/comparison-of-radiation-therapy-modalities-for-hepatocellular-carcinoma-with-portal-vein-thrombosis-a-meta-analysis-and-systematic-review
#2
Chai Hong Rim, Chul Yong Kim, Dae Sik Yang, Won Sup Yoon
PURPOSE: We performed a meta-analysis and systematic review to compare the radiotherapy (RT) modalities for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). MATERIALS AND METHODS: We searched the PubMed, EMBASE, Medline, and Cochrane library databases. The primary endpoint was the 1-year overall survival (OS), and response rate (RR), local control (LC), 2-year OS, and grade ≥3 toxicity incidence were evaluated as secondary endpoints. RESULTS: Thirty-seven studies comprising 2513 patients were included...
December 9, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29217739/y90-radioembolization-for-locally-advanced-hepatocellular-carcinoma-with-portal-vein-thrombosis-long-term-outcomes-in-a-185-patient-cohort
#3
Nadine Abouchaleh, Ahmed Gabr, Rehan Ali, Ali Al Asadi, Ronald A Mora, Joseph Ralph Kallini, Karen Marshall, Laura Kulik, Samdeep Mouli, Daniela P Ladner, Michael Abecassis, Juan C Caicedo, Ahsun Riaz, Robert J Lewandoski, Riad Salem
Purpose: To report survival outcomes for advanced stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with radioembolization (Y90). Methods: With IRB approval we searched our prospectively acquired database for patients treated with Y90 between 2003 and 2017. Inclusion criteria were patients who had advanced stage HCC with tumor PVT. In order to minimize confounding effect, patients with metastases were excluded. Clinical and laboratory data were collected at baseline and 1 month post-Y90...
December 7, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29207378/characteristics-of-hepatocellular-carcinoma-aggressiveness-factors-in-turkish-patients
#4
Hikmet Akkiz, Brian I Carr, Kendal Yalçın K, Vito Guerra, Sedef Kuran, Engin Altıntaş, Oğuz Üsküdar, Ümit Karaoğullarından, Ayşegül Özakyol, Salih Tokmak, Mehmet Yücesoy, Halil İbrahim Bahçeci, Abdulalh Ülkü, Tolga Akçam, Kamil Yalçın Polat, Nazım Ekinci, Halis Şimşek, Necati Örmeci, Abdulalh Sonsuz, Mehmet Demir, Murat Kılıç, Ahmet Uygun, Tuğsan Ballı, Ali Demir, Burcu Arslan, Figen Doran
A large cohort of hepatocellular carcinoma (HCC) patients from several collaborating Turkish institutions were examined for the tumor parameters of maximum diameter (MTD), portal vein thrombosis (PVT), and α-fetoprotein (AFP) levels. A relationship was found between MTD and blood platelet levels. Patients with large ≥5 cm tumors who had normal platelet levels had significantly larger tumors, higher percent of PVT, and significantly lower blood total bilirubin and liver cirrhosis than similar ≥5 cm tumor patients having thrombocytopenia...
December 6, 2017: Oncology
https://www.readbyqxmd.com/read/29190692/transcatheter-arterial-chemoembolization-after-stopping-sorafenib-therapy-for-advanced-hepatocellular-carcinoma
#5
Yao-Kuang Huang, Chieh-Ling Yen, Sz-Iuan Shiu, Shou-Wu Lee, Pi-Yi Chang, Hong-Zen Yeh, Teng-Yu Lee
Targeted therapy is currently the standard treatment for advanced hepatocellular carcinoma (HCC), but an effective treatment after the discontinuation of sorafenib therapy remains uncertain. We aim to investigate the survival benefits of transcatheter arterial chemoembolization (TACE) after stopping sorafenib therapy. We retrospectively analyzed all patients with advanced HCC, who had received palliative TACE after terminating sorafenib therapy, from January 2008 to June 2016. Patients who were in the terminal stage (Child-Pugh class C or performance status 3-4), who received a liver transplantation, or who had received any HCC treatment other than TACE, were excluded...
2017: PloS One
https://www.readbyqxmd.com/read/29186938/occurrence-and-clinical-characteristics-of-hepatocellular-carcinoma-in-the-north-eastern-poland
#6
Paweł Kozłowski, Anna Parfieniuk-Kowerda, Aleksander Tarasik, Marcin Januszkiewicz, Agnieszka Czauż-Andrzejuk, Tadeusz wojciech Łapiński, Robert Flisiak
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of cancerrelated mortality worldwide. Risk factors for this malignancy include liver cirrhosis, HBV or HCV infection, fatty liver disease. THE AIM OF STUDY: This study aims to assess the occurrence and clinical characteristics of HCC in the Northeastern Poland between 2011 and 2015. The number of primary lesions, their size and location within the liver were analysed. The risk factors for this cancer in studied population have been identified...
2017: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/29184683/selective-internal-radiation-therapy-using-yttrium-90-resin-microspheres-in-patients-with-unresectable-hepatocellular-carcinoma-a-retrospective-study
#7
Parvez S Mantry, Ashwini Mehta, Bahar Madani, Alejandro Mejia, Islam Shahin
Background: Selective internal radiation therapy (SIRT) with yttrium-90 resin (Y-90 resin) microspheres has been used as a locoregional therapy for patients with unresectable hepatocellular carcinoma (HCC). We examined patient and disease characteristics that might affect survival after Y-90 resin, as well as treatment tolerability. Methods: Data from patients with unresectable HCC treated with Y-90 resin at a single institution were reviewed retrospectively. Survival was assessed with Kaplan-Meier curves and log-rank tests...
October 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29183764/clinical-outcome-of-portal-vein-thrombosis-in-patients-with-digestive-cancers-a-large-ageo-multicenter-study
#8
Hélène Regnault, Sheik Emambux, Thierry Lecomte, Solene Doat, Marion Dhooge, Marie Besson, Olivier Dubreuil, Frederic Moryoussef, Christine Silvain, Jean-Baptiste Bachet, David Tougeron
INTRODUCTION: Management of portal vein thrombosis (PVT) in cancer patients remains discussed. AIMS: The objective of this multicenter retrospective study was to investigate the management and outcome of PVT in patients with digestive cancers other than hepatocellular carcinoma (HCC). METHOD: Main inclusion criteria were trunk or branch PVT in patients with locally advanced or metastatic digestive cancers. Predictive factors of bleeding and overall survival (OS) were evaluated in univariate and multivariate analysis...
November 16, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29145293/y-configuration-stent-combined-with-iodine-125-seeds-strand-for-the-treatment-of-hepatocellular-carcinoma-with-tumor-thrombosis-in-portal-vein-branches-a-case-report
#9
Tan Tan, Yudong Xiao, Shunke Zhou, Cong Ma, Zishu Zhang
RATIONALE: Currently, the treatment of hepatocellular carcinoma (HCC) associated with portal vein tumor thrombosis (PVTT) is a challenge. Percutaneous puncture endovascular placement of iodine-125 (I) seeds strand and stent is reported to treat HCC with tumor thrombus effectively. However, it is proved to be only suitable for the main portal vein (MPV) thrombus. PATIENT CONCERNS: A 42-year-old male patient was referred to our institution after experiencing right upper abdominal distention without abdominal pain, nausea, or vomiting for 2 weeks...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29137043/portal-vein-thrombosis-before-and-after-transjugular-intrahepatic-portosystemic-shunt-placement-an-observational-study-strobe-compliant
#10
Yue-Meng Wan, Yu-Hua Li, Hua-Mei Wu, Zhi-Yuan Xu, Ying Xu, Li-Hong Yang, Xi-Nan Wu, Jin-Hui Yang
Portal vein thrombosis (PVT) is common in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS). This study had 3-fold aims: to assess risk factors for PVT; to determine the efficacy of anticoagulant therapy; to investigate the impact of PVT on clinical outcomes in TIPS-treated cirrhosis.Between June 2012 and February 2016, 126 TIPS-treated patients with cirrhosis were enrolled and studied prospectively. Enrolled patients were screened for PVT before TIPS and at 3, 6, 12, and 24 months post-TIPS...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29132204/complete-cure-of-advanced-hepatocellular-carcinoma-with-right-adrenal-gland-metastasis-and-portal-vein-thrombosis-by-multiple-applications-of-an-interdisciplinary-therapy-case-report-with-8-year-follow-up
#11
Hojung Jung, Byung Ik Km, Yong Kyun Cho, Woo Kyu Jeon, Hong Joo Kim, Hyun Pyo Hong
Hepatocellular carcinoma (HCC) is the sixth most common cause of death worldwide and the main cause of primary liver cancer. The principle problem of HCC is the poor prognosis, since advanced HCC reportedly has a median survival of only 9 months. The standard therapies are sorafenib and regorafenib, but the outcomes remain unclear. We report a 60-year-old man with advanced HCC with right adrenal gland metastasis and portal vein tumor thrombosis, who showed a complete response to multiple applications of an interdisciplinary therapy...
November 14, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29128147/using-indocyanine-green-extraction-to-predict-liver-function-after-stereotactic-body-radiation-therapy-for-hepatocellular-carcinoma
#12
Krithika Suresh, Dawn Owen, Latifa Bazzi, William Jackson, Randall K Ten Haken, Kyle Cuneo, Mary Feng, Theodore S Lawrence, Matthew J Schipper
PURPOSE: To test the hypothesis that mid-treatment measures of the retention of indocyanine green after 15 minutes (ICGR15) would improve the prediction of posttreatment liver function in the setting of hepatocellular carcinoma. METHODS AND MATERIALS: Between 2006 and 2015, 144 patients with hepatocellular carcinoma received 175 courses of stereotactic body radiation therapy (SBRT). Patient data, such as age, sex, portal vein thrombosis, cirrhosis, Child-Pugh (CP) score, prior liver-directed therapies, and liver function tests, including albumin-bilirubin (ALBI) and ICG clearance, and dosimetric data, such as tumor volume and radiation dose, were collected...
September 22, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29119530/predictors-of-futile-liver-resection-for-patients-with-barcelona-clinic-liver-cancer-stage-b-c-hepatocellular-carcinoma
#13
Chuan Li, Jun-Yi Shen, Xiao-Yun Zhang, Wei Peng, Tian-Fu Wen, Jia-Yin Yang, Lu-Nan Yan
BACKGROUND: There is little information concerning futile liver resection for patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC). This study aimed to establish a predictive model of futile liver resection for patients with BCLC stage B/C HCC. METHODS: The outcomes of 484 patients with BCLC stage B/C HCC who underwent liver resection at our centre between 2010 and 2016 were reviewed. Patients were randomised and divided 2:1 into training and validation sets...
November 8, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29108251/clinical-significance-of-lncrna-atb-expression-in-human-hepatocellular-carcinoma
#14
Se Young Jang, Gyeonghwa Kim, Soo Young Park, Yu Rim Lee, Sang Hoon Kwon, Hyeong Seok Kim, Jun Sik Yoon, Jun Seob Lee, Young-Oh Kweon, Heon Tak Ha, Jae Min Chun, Young Seok Han, Won Kee Lee, Jun Young Chang, Jung Gil Park, Byungheon Lee, Won Young Tak, Keun Hur
Hepatocellular carcinoma (HCC) is a worldwide health problem and it is important to understand the mechanistic roles of the biomolecules involved in its pathogenesis. Long non-coding RNAs (lncRNAs) are frequently and aberrantly expressed in various human cancers and are known to play a role in cancer pathogenesis. The aim of this study was to analyze the expression of lncRNA-ATB in HCC and investigate the implications for prognoses. In total, 100 samples of HCC tissues and their corresponding, adjacent, non-cancerous liver tissues were collected...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29067511/safety-and-efficacy-of-transarterial-radioembolization-combined-with-chemoembolization-for-bilobar-hepatocellular-carcinoma-a-single-center-retrospective-study
#15
Joon Ho Kwon, Gyoung Min Kim, Kichang Han, Jong Yun Won, Man Deuk Kim, Do Yun Lee, Junhyung Lee, Woosun Choi, Yong Seek Kim, Do Young Kim, Kwang-Hyub Han
BACKGROUND: Radioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Nineteen patients (mean age 60 years; range 27-82 years) treated for HCC between June 2012 and September 2014 were included in the analysis...
October 24, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29066120/stereotactic-body-radiation-therapy-as-an-alternative-to-transarterial-chemoembolization-for-hepatocellular-carcinoma
#16
Eli Sapir, Yebin Tao, Matthew J Schipper, Latifa Bazzi, Paula M Novelli, Pauline Devlin, Dawn Owen, Kyle C Cuneo, Theodore S Lawrence, Neehar D Parikh, Mary Feng
PURPOSE: To conduct a large single-institution comparison of transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT) outcomes in similar groups of patients with hepatocellular carcinoma (HCC). METHODS AND MATERIALS: From 2006 to 2014, 209 patients with 1 to 2 tumors underwent TACE (n=84) to 114 tumors or image guided SBRT (n=125) to 173 tumors. Propensity score analysis with inverse probability of treatment weighting was used to compare outcomes between treatments while adjusting for imbalances in treatment assignment...
September 14, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28974984/transarterial-infusion-of-epirubicin-and-cisplatin-combined-with-systemic-infusion-of-5-fluorouracil-versus-transarterial-chemoembolization-using-doxorubicin-for-unresectable-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-a-retrospective-analysis
#17
Sung Won Lee, Hae Lim Lee, Nam Ik Han, Jung Hyun Kwon, Soon Woo Nam, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
BACKGROUND: More than one-third of hepatocellular carcinoma (HCC) patients are diagnosed at advanced stage with portal vein tumor thrombosis (PVTT) or extrahepatic metastasis. However, the outcomes of current therapeutic approaches are unsatisfactory. As a novel therapeutic strategy for unresectable HCC with PVTT, we analyzed the outcomes of transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil (TAC-ECF) and compared its therapeutic effects and toxicity with transarterial chemoembolization (TACE) using doxorubicin (DOX)...
October 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28927132/downregulation-of-esophageal-cancer-related-gene-4-promotes-proliferation-and-migration-of-hepatocellular-carcinoma
#18
Shujian Ge, Yali Xu, Hongliang Wang, Yaxin Sun, Xiangguo Tian, Zhixin Cao, Xiaoyan Lin, Jiawen Xu, Qiangxiu Wang
Esophageal cancer-related gene 4 (ECRG4) is a candidate tumor suppressor gene, which is involved in cell apoptosis, migration, infection and inflammation responsiveness; however, its expression level and clinical significance in hepatocellular carcinoma (HCC) remains unclear. In the present study, the authors aim to evaluate the clinical significance and potential role of ECRG4 in HCC. Level of ECRG4 protein expression in HCC and peripheral tissues was investigated in tissue specimens obtained from 56 consecutive HCC patients by immunohistochemistry...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28923632/liver-transplantation-in-patients-with-complete-portal-vein-thrombosis-renoportal-or-varicoportal-anastomosis-using-cryopreserved-vein-grafts
#19
H Aktas, A Ozer, O S Guner, E Gurluler, R Emiroglu
BACKGROUND: Despite technical developments in transplantation surgery, complete portal vein thrombosis still remains a challenge for restoration of adequate portal vein inflow. Renoportal or varicoportal anastomosis provides an effective alternative solution for patients with complete portal vein thrombosis. This study describes our experience with renoportal and varicoportal anastomosis during liver transplantation. PATIENTS AND METHODS: Between January 2014 and May 2016, 5 patients with complete portal vein thrombosis underwent extra-anatomic portal anastomosis...
October 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28922192/differentiation-of-malignant-thrombus-from-bland-thrombus-of-the-portal-vein-in-patient-with-hepatocellular-carcinoma-on-18f-fdg-pet-ct
#20
Krishan Kant Agarwal, Dipalkumar Shah, Neha Shah, Manas Mayank
Hepatocellular carcinoma carries a high risk of invasion of the portal vein. Neoplastic and bland portal vein thrombi discrimination is of great clinical significance for determining the therapeutic approach, predicting survival, and assessing candidates for liver transplantation. F-FDG PET/CT may be helpful in discriminating between malignant and portal vein thrombi. We present the case of a 61-year old man who presented with hepatocellular carcinoma with portal vein involvement. F-FDG PET/CT has a role in differentiating malignant from benign portal vein thrombosis...
September 15, 2017: Clinical Nuclear Medicine
keyword
keyword
77310
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"